Previous 10 | Next 10 |
Guardion Health Sciences (NASDAQ:GHSI) +53%. RISE Education Cayman (NASDAQ:REDU) +20% on receipt of prelim non-bidding proposal to acquire all company assets Kaival Brands Innovations (NASDAQ:KAVL) +25% FDA enters administrative stay of Bidi Vapor's marketing denial order for i...
6 out of 7 patients (85.7%) showed clinical remission (PGA score ≤ 1) and closure of target ulcer in the highest dose cohort Treatment was well tolerated; no dose-related adverse events observed Final post treatment observational data will be available in the first half o...
Gainers: AlloVir (NASDAQ:ALVR) +14%, InflaRx (NASDAQ:IFRX) +14%, Harmony Biosciences (NASDAQ:HRMY) +13%, Omeros (NASDAQ:OMER) +11%, Prelude Therapeutics (NASDAQ:PRLD) +11%. Losers: Galera Therapeutics (NASDAQ:GRTX) -68%, Atea Pharmaceutic...
Energous (NASDAQ:WATT) +35% granted FCC approval for unlimited Distance over-the-air wireless charging Edesa Biotech (NASDAQ:EDSA) +29% reports favorable mortality reductions in COVID-19 study InflaRx (NASDAQ:IFRX) +21% after EUR 43.7M vilobelimab development grant En...
Initial portion of the grant amounts to EUR 25.8 million Remainder of the grant will be awarded in three additional milestone-dependent tranches JENA, Germany, Oct. 19, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing ...
R. R. Donnelley & Sons (NYSE:RRD) +31%. Inhibrx (NASDAQ:INBX) +17% on favorable safety profile in patients with alpha-1 antitrypsin deficiency and demonstrates the potential to achieve normal alpha-1 antitrypsin levels with monthly dosing. Protara Therapeutics (NASDAQ:TARA) +26%...
Study has enrolled 369 patients across 9 countries Topline results expected to be available in Q1 2022 JENA, Germany, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targetin...
ChemoCentryx CCXI +71% on FDA approval of Tavneos for treatment of vasculitis (updated) Camber Energy (NYSE:CEI) +33%. eFFECTOR Therapeutics EFTR +22% after-hours on encouraging zotatifin data in breast cancer InflaRx N.V. (NASDAQ:IFRX) +18%. Immuron (NASDAQ:IMRN) +16%. Fo...
JENA, Germany, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces that Prof. Niels C. Riedemann, Chief Executive Officer and Founder, will present a com...
Kadmon Holdings (NASDAQ:KDMN) +74% Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B Gain Therapeutics (NASDAQ:GANX) +27% on positive GT-02287and GT-02329 data in Parkinson’s disease Alset EHome International (NASDAQ:AEI) +15% inv...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...